Planck Standard
Politics

White House Pulls Heidi Overton's FDA Nomination Hours Before Senate Committee Vote

Sen. Bill Cassidy says the administration 'abandoned a viable confirmation path' after pro-life senators sought new assurances, leaving the FDA without a confirmed chief as Democrats near control of the Senate.

White House Pulls Heidi Overton's FDA Nomination Hours Before Senate Committee Vote
Video via YouTube

The White House has dropped the nomination of Dr. Heidi Overton, President Trump's pick to run the Food and Drug Administration, according to a senior administration official and other people familiar with the decision. The move came on the eve of a scheduled vote on her nomination in the Senate Health, Education, Labor and Pensions Committee, which was set to act on Wednesday.

Axios was first to report that Overton had been dropped. Two sources familiar with the matter told CBS News the White House shared its decision to withdraw the nomination on Tuesday evening. At that point, Republican whip efforts to line up enough votes to advance her were still underway, according to the sources, which suggests the decision was made before the vote count had been settled either way.

Republican Sen. Bill Cassidy of Louisiana, the outgoing chair of the HELP Committee, said late Tuesday the problem was not a shortage of votes. He argued instead that the White House walked away from a nomination that could have been confirmed. "White House abandoned a viable confirmation path," Cassidy wrote in a statement. He said "pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues," and that the administration chose to withdraw Overton rather than provide them.

Cassidy said his own conversations with Overton had convinced him she would pass out of committee and win a full Senate vote. "My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk," he said. Overton had appeared before senators in September, when she told them vaccines are safe.

The agency is currently run by acting Commissioner Kyle Diamantas. Earlier on Tuesday, a source told CBS News the White House had already begun talking to other potential candidates for the job, including some who could serve in an acting capacity and so avoid the need for Senate confirmation. Two sources indicated that Sen. Roger Marshall of Kansas, a physician, is making a play for the post. Marshall lost his reelection bid earlier this month to Democrat Adam Hamilton.

Time is the central constraint. Any Senate-confirmed FDA commissioner would have to be approved in the narrow window that remains before Democrats take control of the chamber in January. Cassidy told CBS News on Tuesday that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats." The Senate is also dealing with other nominations and priorities in the lame-duck weeks, which leaves little floor time for a new nominee who would first need a hearing and a committee vote.

Cassidy framed the stakes as a choice about how the agency is led. "The question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody's mind, but at least would be a permanent one and have the ability to establish some independence?" he said.

The FDA regulates prescription drugs, vaccines, medical devices and much of the nation's food supply, and a vacancy at the top leaves those decisions in the hands of an acting leader. The White House has not named a replacement nominee, and it did not publicly detail what assurances the pro-life senators wanted. What happens next depends on whether the administration tries to install an acting commissioner, finds a new nominee who can move through the Senate in a few weeks, or leaves the choice to the incoming Democratic majority.

Read next